Literature DB >> 20594548

Bone turnover markers in Spanish adult men The Camargo Cohort Study.

José M Olmos1, José L Hernández, Josefina Martínez, Emilio Pariente, Javier Llorca, Jesús González-Macías.   

Abstract

BACKGROUND: This cross-sectional study was performed to determine the reference ranges for two bone turnover markers-aminoterminal propeptide of type I collagen (P1NP) and C-terminal telopeptide of type I collagen (beta-CTX)-in normal adult Spanish men as measured in serum by automated methods.
METHODS: A community-based population of 660 healthy men > or = 50 years was evaluated. Fasting serum levels of P1NP, beta-CTX, 25-hydroxyvitamin D, and intact parathyroid hormone were measured on the Elecsys 2010 automated analyzer (Roche). BMD at lumbar spine, femoral neck and total hip was determined by DXA.
RESULTS: Mean age of participants was 65 + or - 9 years. Logarithmic transformation of both markers was performed to allow for normal distribution. Mid-95% ranges for P1NP and beta-CTX were 15-78 ng/ml and 0.069-0.760 ng/ml, respectively. Median and interquartile range of serum P1NP and beta-CTX were 33.5 [25.5;44.4] ng/ml and 0.27 [0.19;0.38] ng/ml, respectively. Mean values of P1NP (37.1 + or - 16.7 ng/ml) were similar to those previously described. beta-CTX mean values (0.300 + or - 0.171 ng/ml) were also similar to those quoted by the manufacturers in men younger than 70 years, but slightly lower than those reported in subjects older than 70 years. Both markers were higher among osteoporotic men. After excluding from the analysis those men who were found to have BMD below -2.5 T-score, 25OHD serum level below 30 ng/ml or serum PTH above 65 pg/ml, P1NP and beta-CTX ranges were 17-71 ng/ml and 0.070-0.681 ng/ml, again respectively.
CONCLUSIONS: Values obtained from this well-characterized population study provide reference ranges for serum automated P1NP and beta-CTX in normal Spanish adult men. Copyright 2010 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20594548     DOI: 10.1016/j.cca.2010.06.010

Source DB:  PubMed          Journal:  Clin Chim Acta        ISSN: 0009-8981            Impact factor:   3.786


  10 in total

1.  No Associations of 25-Hydroxycholecalciferol and Parathyroid Hormone Concentrations with Calcaneal Bone Characteristics in Community-Dwelling Elderly Subjects: A Cross-Sectional Study.

Authors:  A Jungert; M Neuhäuser-Berthold
Journal:  J Nutr Health Aging       Date:  2017       Impact factor: 4.075

2.  Prevalence of vertebral fracture and densitometric osteoporosis in Spanish adult men: The Camargo Cohort Study.

Authors:  José M Olmos; José L Hernández; Josefina Martínez; Emilio Pariente; Jesús Castillo; Daniel Prieto-Alhambra; Jesús González-Macías
Journal:  J Bone Miner Metab       Date:  2017-01-19       Impact factor: 2.626

3.  Serum 25-hydroxyvitamin D, parathyroid hormone, calcium intake, and bone mineral density in Spanish adults.

Authors:  J M Olmos; J L Hernández; P García-Velasco; J Martínez; J Llorca; J González-Macías
Journal:  Osteoporos Int       Date:  2015-07-02       Impact factor: 4.507

4.  A systematic review of vitamin D status in southern European countries.

Authors:  Yannis Manios; George Moschonis; Christina-Paulina Lambrinou; Konstantina Tsoutsoulopoulou; Panagiota Binou; Alexandra Karachaliou; Christina Breidenassel; Marcela Gonzalez-Gross; Mairead Kiely; Kevin D Cashman
Journal:  Eur J Nutr       Date:  2017-10-31       Impact factor: 5.614

Review 5.  Harmonised Australian Reference Intervals for Serum PINP and CTX in Adults.

Authors:  Samuel D Vasikaran; Sa Paul Chubb; Peter R Ebeling; Nicole Jenkins; Graham Rd Jones; Mark A Kotowicz; Howard A Morris; Hans-Gerhard Schneider; Markus J Seibel; Greg Ward
Journal:  Clin Biochem Rev       Date:  2014-11

6.  Comparison of two automated assays of BTM (CTX and P1NP) and reference intervals in a Danish population.

Authors:  N R Jørgensen; L T Møllehave; Y B L Hansen; N Quardon; L Lylloff; A Linneberg
Journal:  Osteoporos Int       Date:  2017-04-28       Impact factor: 4.507

7.  Bone mineral density in statin users: a population-based analysis from a Spanish cohort.

Authors:  José L Hernández; José M Olmos; Galo Romaña; Josefina Martinez; Jesús Castillo; Irina Yezerska; Gabriel Pinedo; Jesús González-Macías
Journal:  J Bone Miner Metab       Date:  2013-06-20       Impact factor: 2.626

8.  Bone Turnover Status: Classification Model and Clinical Implications.

Authors:  Alexander Fisher; Leon Fisher; Wichat Srikusalanukul; Paul N Smith
Journal:  Int J Med Sci       Date:  2018-02-01       Impact factor: 3.738

9.  Reference intervals for serum osteocalcin concentrations in adult men and women from the study of health in Pomerania.

Authors:  Anke Hannemann; Nele Friedrich; Christin Spielhagen; Rainer Rettig; Till Ittermann; Matthias Nauck; Henri Wallaschofski
Journal:  BMC Endocr Disord       Date:  2013-03-13       Impact factor: 2.763

10.  Genome-wide association study for radiographic vertebral fractures: a potential role for the 16q24 BMD locus.

Authors:  Ling Oei; Karol Estrada; Emma L Duncan; Claus Christiansen; Ching-Ti Liu; Bente L Langdahl; Barbara Obermayer-Pietsch; José A Riancho; Richard L Prince; Natasja M van Schoor; Eugene McCloskey; Yi-Hsiang Hsu; Evangelos Evangelou; Evangelia Ntzani; David M Evans; Nerea Alonso; Lise B Husted; Carmen Valero; Jose L Hernandez; Joshua R Lewis; Stephen K Kaptoge; Kun Zhu; L Adrienne Cupples; Carolina Medina-Gómez; Liesbeth Vandenput; Ghi Su Kim; Seung Hun Lee; Martha C Castaño-Betancourt; Edwin H G Oei; Josefina Martinez; Anna Daroszewska; Marjolein van der Klift; Dan Mellström; Lizbeth Herrera; Magnus K Karlsson; Albert Hofman; Östen Ljunggren; Huibert A P Pols; Lisette Stolk; Joyce B J van Meurs; John P A Ioannidis; M Carola Zillikens; Paul Lips; David Karasik; André G Uitterlinden; Unnur Styrkarsdottir; Matthew A Brown; Jung-Min Koh; J Brent Richards; Jonathan Reeve; Claes Ohlsson; Stuart H Ralston; Douglas P Kiel; Fernando Rivadeneira
Journal:  Bone       Date:  2014-02       Impact factor: 4.398

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.